Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Arcus

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday.

Benzinga

Why Roche's Accidental Cancer Update Boosted Several Rivals By As Much As 22%

Roche accidentally published positive interim results from a lung cancer treatment study, which boosted shares of rivals Iteos and Arcus.

Investors Business Daily

ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Dips

ImmunoGen and Day One unveiled promising cancer treatment updates over the weekend, leading IMGN stock and DAWN stock to soar Monday.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Arcus, Iteos Soar On Roche's 'Meaningful' Results In A New Cancer Drug Class

Shares of Arcus and Iteos surged Friday after Roche provided "meaningful" evidence for a new cancer treatment class.

Investors Business Daily

Tyneside animation firm Arcus Studios set for growth with £150,000 investment

The Newcastle company works with the likes of BBC, E4 and the McMillan Trust and is set to create jobs

Birmingham Post

Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche

Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. RCUS stock skidded more than 20%.

Investors Business Daily

Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges

Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Biotech Stocks Hammered On Roche's Unexpected Failure In Lung Cancer

A Roche failure in lung cancer sent a ripple through biotech stocks on Wednesday, toppling Arcus, BeiGene, Iteos and others.

Investors Business Daily

Arcus Posts Encouraging Data For Domvanalimab-Based Regimes In Lung Cancer Settings

Arcus Biosciences Inc (NYSE:RCUS) announced results from the third interim analysis of the ongoing Phase 2 ARC-7 study of zimberelimab vs. domvanalimab plus zimberelimab (doublet) vs. domvanalimab plus zimberelimab and etrumadenant (triplet) as a first-line treatment for metastatic non-small cell lung cancer. In this interim analysis, both domvanalimab-containing arms continued to show meaningful…

Benzinga

People

Brian Abrahams

70 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

North of Tyne Combined Authority

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.